Celgene (NASDAQ:CELG) turned in a quarter that beat analyst expectations on the top and bottom lines, with revenue up 17% year-over-year and adjusted EPS up 18% year-over-year, yet the market didn't appear too impressed (the stock sold off about 3% today).

In the video below, Motley Fool health care analysts Michael Douglass and David Williamson dive into the key takeaways from earnings.